



*Achieving tomorrow's outcomes  
through education today.™*

## RARE DISEASES Symposium

August 24, 2024 – Westin Indianapolis

5.5 CME and MOC points

Limited Time – No Registration Fee for Treating  
Providers

Indy Hematology Education is a nonprofit educational organization that focuses on educating providers on malignant conditions to increase knowledge, enhance awareness, and, ultimately, improve outcomes for patients with malignant conditions. Rare diseases frequently treated in the community can pose a major challenge to treating physicians, advanced practitioners, and nurses. Additionally, there is sometimes a lack of consensus criteria for the management of these disorders. The rarity of the disease states further exacerbates these issues; therefore, there are infrequent presentations to treating physicians who have difficulty establishing significant expertise in treating these rare conditions. However, despite the rarity of these diseases, most patients are treated in the community. Thus, the education of providers in community practice is imperative and warranted in order to promote a better understanding of the diagnosis, treatment, and emerging therapeutics for the management of these disorders.

Given the above, Indy Hematology Education is proposing a Rare Diseases Symposium for Indianapolis in 2024. This meeting would result in an invitation of leading physicians from across the globe and the United States to present current and emerging practice products and diagnostic strategies for these rare disorders. We intend to cover pathology and the interpretation of NGS studies in the treatment of acute leukemias, mastocytosis, and lymphomas. Additionally, we would provide practical strategies and a tool kit for the management of acute leukemias in community practice, including patients with driver mutations, those who are ineligible for intensive chemotherapy, and the treatment of acute lymphoblastic leukemia. Additionally, we will cover the treatment of the exceedingly rare condition of Blastic Plasmacytoid Dendritic Cell Neoplasm. This rare leukemia is usually associated with fatality, and an understanding of emerging treatment and diagnostic strategies, as well as other management options, will be discussed. Other diseases to be addressed would include T-cell lymphomas and leukemias and hematologic conditions, including Cold Agglutinin Disease, Thrombotic Thrombocytopenic Purpura, Paroxysmal Nocturnal Hemoglobinemia, Hemophagocytic Lymphocytosis, and Porphyrias, as well as Systemic Mastocytosis. In addition, the treatment of rare plasma cell dyscrasias, monoclonal gammopathy of renal significance, POEMS syndrome, Castleman disease, and amyloidosis will be addressed. Emerging options for the treatment of patients with neoplastic disorders with driver mutations has become an increasing challenge for treating providers. Therefore, we would address and discuss molecular pathology and diagnostics of neoplastic conditions including, but not limited to, lung cancer, and the utility of targeted and driver mutational targeted therapy in the treatment of lung cancer as well as immunotherapy including bispecific antibody therapy in the treatment of nonsmall cell and small cell lung cancer.

Furthermore, approaches to the management of cancer in a tumor agnostic manner with targeted therapies will be thoroughly reviewed and discussed. We believe at the end of this symposium, attending providers will be better equipped in their understanding of these rare disorders and in the treatment of patients presenting to their practices yielding an improvement of treatment and therapeutic outcomes. We invite all to support this important endeavor, and we hope that your support will continue to enhance the outcomes of patients treated within our practice.

## Rare Diseases Symposium - Chair: Ruemu E. Birhiray, MD and Co-Chair: Sumeet Bhatia, MD

Saturday, August 24 <sup>th</sup> 7:50AM - 7:55AM	Introduction and Welcome: What We Do: Treatment of Rare Diseases in Community Oncology Practices   <b>Ruemu Birhiray, MD, President/CEO, Indy Hematology Education, Inc.</b>
7:55AM - 8:15AM	How we diagnose and treat Systemic Mastocytosis   <b>Tsewang Tashi, MD, Hematologist, Huntsman Cancer Institute</b>
8:15AM - 8:35AM	Practical Strategies for Managing Leukemias in Community Oncology: Managing the Patient Who is Not Eligible for Intensive Chemotherapy, and Small Molecule Targeted Therapy in Community Oncology Practices   <b>Michael Thirman, MD, Associate Professor of Medicine, University of Chicago</b>
8:35AM - 8:50AM	BREAK
8:50AM - 9:10AM	Heralding The Era of Curable Therapy for Acute Lymphoblastic Leukemia: Monoclonal Antibodies and Targeted Therapy in Community Oncology   <b>Mark Robert Litzow, MD, Professor of Medicine, Mayo Clinic School of Graduate Medical Education</b>
9:10AM - 9:35AM	How We Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)   <b>Anthony Stein, Professor, City of Hope</b>
9:35AM - 10:00AM	Contemporary Approaches to the Management of T-Cell Lymphomas/Leukemias   <b>Francine Foss, MD, Professor of Medicine, Smilow Comprehensive Cancer Center, Yale School of Medicine</b>
10:00AM - 10:20AM	Acute Leukemia and Lymphoma Panel Discussion
10:20AM - 10:35AM	BREAK
10:35AM - 11:00AM	Anxiety Inducing Hematologic Disorders: Managing the Patient with Cold Agglutinin Disease, Thrombotic Thrombocytopenic Purpura and Paroxysmal Nocturnal Hemoglobinuria   <b>Catherine Broome, MD, Professor of Medicine, MedStar Georgetown University Hospital</b>
11:00AM - 11:25AM	Current Approaches to the Management of Hemophagocytic Lymphohistiocytosis: Recognition, Diagnosis and Treatment   <b>Lorisa Broglie, MD, MS, Associate Professor of Pediatrics, Medical College of Wisconsin</b>
11:25AM - 11:40AM	BREAK
11:40AM - 12:05AM	Recognizing and Treatment of Porphyrias: Evaluation and Management   <b>Herbert Bonkovsky, MD, Professor of Medicine and Molecular Medicine &amp; Translational Science, Wake Forest University School of Medicine</b>
12:05AM - 12:30PM	Approaches and Treatment of Rare Plasma Cell Dyscrasias: Monoclonal Gammopathy of Renal Significance, POEMS Syndrome, Castleman Disease and Amyloidosis   <b>Angela Dispenzieri, MD, Professor of Medicine, Mayo Clinic</b>
12:30PM - 12:50PM	Q/A and Panel Discussion
12:50PM - 1:05PM	BREAK
1:05PM - 2:05PM	LUNCH/Product Theater
2:05PM - 2:25PM	Immunotherapy and T-Cell Directed Approaches to the Management of Small Cell Lung Cancer   <b>Kai He, MD, PhD, Associate Professor with Tenure, The Ohio State University</b>
2:25PM - 2:50PM	Understanding Molecular Pathology and Targeting the Bulls Eye in Cancer Therapy: Targeted Therapy for Lung Cancer: Approaches to the Management of Patients with DRIVER Mutations   <b>Vivek Subbiah, Sarah Cannon Cancer institute</b>
2:50PM - 3:15PM	“The No Name Cancer”: When All That Matters is Targeting the Tumor – Tumor Agnostic Therapy in Cancer Management   <b>Razelle Kurzrock, MD, Professor of Medicine, Associate Director, Clinical Research, Medical College of Wisconsin</b>
3:15PM - 3:25PM	Q/A and Panel Discussion
3:25PM - 3:30PM	Adjourn   <b>Ruemu Birhiray, MD, President/CEO, Indy Hematology Education, Inc.</b>
3:30PM - 4:30PM	Meet the Professor and Reception